Minerva Neurosciences Company Profile (NASDAQ:NERV)

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $316.69 million
  • Outstanding Shares: 42,509,000
Average Prices:
  • 50 Day Moving Avg: $7.26
  • 200 Day Moving Avg: $7.62
  • 52 Week Range: $5.55 - $14.15
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.84
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.67 per share
  • Price / Book: 2.79
Profitability:
  • EBITDA: ($37,690,000.00)
  • Return on Equity: -36.13%
  • Return on Assets: -28.47%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 5.35%
  • Quick Ratio: 5.35%
Misc:
  • Average Volume: 221,078 shs.
  • Beta: 1.72
  • Short Ratio: 6.67
 

Frequently Asked Questions for Minerva Neurosciences (NASDAQ:NERV)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc (NASDAQ:NERV) posted its earnings results on Thursday, August, 3rd. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.34) by $0.07. During the same period in the prior year, the business earned ($0.18) EPS. View Minerva Neurosciences' Earnings History.

When will Minerva Neurosciences make its next earnings announcement?

Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Minerva Neurosciences.

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?

3 equities research analysts have issued 12-month price objectives for Minerva Neurosciences' stock. Their forecasts range from $11.00 to $20.00. On average, they anticipate Minerva Neurosciences' stock price to reach $16.00 in the next twelve months. View Analyst Ratings for Minerva Neurosciences.

What are analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:

  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/5/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:

  • Marc D. Beer, Independent Chairman of the Board
  • Remy Luthringer Ph.D., President, Chief Executive Officer, Director
  • Geoffrey Race, Executive Vice President and Chief Financial Officer
  • Joseph Reilly, Chief Operating Officer, Vice President
  • Frederick Ahlholm CPA, Chief Accounting Officer, Vice President
  • Mark Levine, Vice President, General Counsel, Secretary
  • David J Kupfer M.D., Independent Director
  • Fouzia Laghrissi-Thode M.D., Independent Director
  • G. J. van Heek, Independent Director

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $7.45.


MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  203
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.00 (114.77% upside)
Consensus Price Target History for Minerva Neurosciences (NASDAQ:NERV)
Price Target History for Minerva Neurosciences (NASDAQ:NERV)
Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/1/2017Citigroup Inc.Initiated CoverageBuy$11.00HighView Rating Details
6/1/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $20.00LowView Rating Details
3/6/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$17.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Earnings History by Quarter for Minerva Neurosciences (NASDAQ NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/3/2017Q2 2017($0.34)($0.27)ViewListenView Earnings Details
5/4/2017Q1 2017($0.30)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
2017 EPS Consensus Estimate: ($1.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Minerva Neurosciences (NASDAQ:NERV)
Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 69.29%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.00View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.62View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.00View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.00View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.00View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Minerva Neurosciences (NASDAQ:NERV)
Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
Source:
Loading headlines, please wait.

Social

Chart

Minerva Neurosciences (NERV) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.